{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,8]],"date-time":"2026-08-08T13:44:01Z","timestamp":1786196641702,"version":"build-2736575974"},"reference-count":55,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/100000030","name":"Centers for Disease Control and Prevention","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000030","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000016","name":"U.S. Department of Health and Human Services","doi-asserted-by":"publisher","award":["R49CE003565"],"award-info":[{"award-number":["R49CE003565"]}],"id":[{"id":"10.13039\/100000016","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","jsatjournal.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Substance Use and Addiction Treatment"],"published-print":{"date-parts":[[2026,11]]},"DOI":"10.1016\/j.josat.2026.210060","type":"journal-article","created":{"date-parts":[[2026,7,2]],"date-time":"2026-07-02T16:45:46Z","timestamp":1783010746000},"page":"210060","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["Methadone treatment in the rural and urban United States: Geographic barriers and regional variations in Medicare-enrolled opioid treatment program availability"],"prefix":"10.1016","volume":"190","author":[{"given":"Sara C.","family":"Woolcock","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C. Holly A.","family":"Andrilla","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brittany E.","family":"Blanchard","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Megan","family":"Moore","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Claire B.","family":"Simon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Janessa M.","family":"Graves","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.josat.2026.210060_bb0005","author":"42 CFR Part 8 - Medications for the Treatment of Opioid Use Disorder"},{"issue":"1","key":"10.1016\/j.josat.2026.210060_bb0010","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1007\/s13311-019-00814-4","article-title":"Availability of medications for the treatment of alcohol and opioid use disorder in the U.S.A","volume":"17","author":"Abraham","year":"2020","journal-title":"Neurotherapeutics"},{"key":"10.1016\/j.josat.2026.210060_bb0015","doi-asserted-by":"crossref","DOI":"10.1016\/j.josat.2023.209247","article-title":"Introduction of Medicare coverage in opioid treatment programs: Findings from the first three years","volume":"158","author":"Abraham","year":"2024","journal-title":"Journal of Substance Use and Addiction Treatment"},{"key":"10.1016\/j.josat.2026.210060_bb0020","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1016\/j.jsat.2018.07.006","article-title":"Increased distance was associated with lower daily attendance to an opioid treatment program in Spokane County Washington","volume":"93","author":"Amiri","year":"2018","journal-title":"Journal of Substance Abuse Treatment"},{"issue":"2","key":"10.1016\/j.josat.2026.210060_bb0025","doi-asserted-by":"crossref","first-page":"188","DOI":"10.1016\/j.jval.2020.08.2098","article-title":"Disparities in access to opioid treatment programs and office-based buprenorphine treatment across the rural-urban and area deprivation continua: A U.S. nationwide small area analysis","volume":"24","author":"Amiri","year":"2021","journal-title":"Value in Health"},{"key":"10.1016\/j.josat.2026.210060_bb0030","article-title":"Disparities in access to opioid treatment programs and buprenorphine providers by race and ethnicity in the contiguous U.S.","author":"Amiri","year":"2023","journal-title":"Journal of Substance Use and Addiction Treatment"},{"issue":"1","key":"10.1016\/j.josat.2026.210060_bb0035","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1111\/jrh.12328","article-title":"Overcoming barriers to prescribing buprenorphine for the treatment of opioid use disorder: Recommendations from rural physicians","volume":"35","author":"Andrilla","year":"2019","journal-title":"The Journal of Rural Health"},{"issue":"1","key":"10.1016\/j.josat.2026.210060_bb0040","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1111\/jrh.12569","article-title":"Tracking the geographic distribution and growth of clinicians with a DEA waiver to prescribe buprenorphine to treat opioid use disorder","volume":"38","author":"Andrilla","year":"2022","journal-title":"The Journal of Rural Health"},{"key":"10.1016\/j.josat.2026.210060_bb0045","author":"Andrilla"},{"issue":"1","key":"10.1016\/j.josat.2026.210060_bb0050","doi-asserted-by":"crossref","first-page":"999","DOI":"10.1080\/08897077.2022.2060430","article-title":"Accuracy of publicly-listed locator information for buprenorphine waivered practitioners and opioid treatment programs in the U.S., 2020","volume":"43","author":"Barenie","year":"2022","journal-title":"Substance Abuse"},{"issue":"5","key":"10.1016\/j.josat.2026.210060_bb0055","doi-asserted-by":"crossref","first-page":"889","DOI":"10.1007\/s11113-020-09606-7","article-title":"Population change and income inequality in rural America","volume":"39","author":"Butler","year":"2020","journal-title":"Population Research and Policy Review"},{"issue":"11","key":"10.1016\/j.josat.2026.210060_bb0060","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2022.41128","article-title":"Patterns in geographic distribution of substance use disorder treatment facilities in the U.S. and accepted forms of payment from 2010 to 2021","volume":"5","author":"Cantor","year":"2022","journal-title":"JAMA Network Open"},{"key":"10.1016\/j.josat.2026.210060_bb0065","author":"Center for Medicare and Medicaid Services"},{"key":"10.1016\/j.josat.2026.210060_bb0070","series-title":"Medicare monthly enrollment (version March 2025) [dataset]","author":"Centers for Medicare & Medicaid Services","year":"2025"},{"key":"10.1016\/j.josat.2026.210060_bb0075","series-title":"Opioid treatment program providers (version June 17, 2025) [dataset]","author":"Centers for Medicare & Medicaid Services","year":"2025"},{"key":"10.1016\/j.josat.2026.210060_bb0080","series-title":"CMS-RHT-26-001 rural health transformation program notice of funding opportunity","author":"Centers for Medicare & Medicaid Services","year":"2025"},{"key":"10.1016\/j.josat.2026.210060_bb0085","author":"Comprehensive Addiction and Recovery Act of 2016"},{"key":"10.1016\/j.josat.2026.210060_bb0090","series-title":"Rural and urban pharmacy presence\u2013Pharmacy deserts (policy brief nos. 2022\u20131)","author":"Constantin","year":"2022"},{"key":"10.1016\/j.josat.2026.210060_bb0095","doi-asserted-by":"crossref","DOI":"10.1016\/j.drugalcdep.2022.109495","article-title":"County-level sociodemographic differences in availability of two medications for opioid use disorder: United States, 2019","volume":"236","author":"Corry","year":"2022","journal-title":"Drug and Alcohol Dependence"},{"key":"10.1016\/j.josat.2026.210060_bb0100","author":"Drug Addiction Treatment Act of 2000"},{"key":"10.1016\/j.josat.2026.210060_bb0105","series-title":"Urban influence codes [dataset]","author":"Economic Research Service","year":"2024"},{"key":"10.1016\/j.josat.2026.210060_bb0110","series-title":"County typology codes [dataset]","author":"Economic Research Service","year":"2025"},{"key":"10.1016\/j.josat.2026.210060_bb0115","series-title":"The new mobile methadone rules and what they mean for treatment access","author":"El-Sabawi","year":"2021"},{"issue":"3","key":"10.1016\/j.josat.2026.210060_bb0120","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1177\/10600280211028262","article-title":"Pronounced regional disparities in United States methadone distribution","volume":"56","author":"Furst","year":"2022","journal-title":"Annals of Pharmacotherapy"},{"issue":"11","key":"10.1016\/j.josat.2026.210060_bb0125","doi-asserted-by":"crossref","DOI":"10.1001\/jamapediatrics.2018.2143","article-title":"Receipt of timely addiction treatment and association of early medication treatment with retention in care among youths with opioid use disorder","volume":"172","author":"Hadland","year":"2018","journal-title":"JAMA Pediatrics"},{"issue":"7","key":"10.1016\/j.josat.2026.210060_bb0130","doi-asserted-by":"crossref","first-page":"991","DOI":"10.1377\/hlthaff.2023.00148","article-title":"Changes in county-level access to medications for opioid use disorder after Medicare coverage of methadone treatment began","volume":"42","author":"Harris","year":"2023","journal-title":"Health Affairs"},{"issue":"1","key":"10.1016\/j.josat.2026.210060_bb0135","doi-asserted-by":"crossref","DOI":"10.1080\/07853890.2024.2306492","article-title":"Engaging the great circle: A qualitative study of the Confederated Tribes of Grand Ronde\u2019s mobile medication unit","volume":"56","author":"Hoffman","year":"2024","journal-title":"Annals of Medicine"},{"key":"10.1016\/j.josat.2026.210060_bb0140","author":"Idaho Office of Drug Policy"},{"key":"10.1016\/j.josat.2026.210060_bb0145","doi-asserted-by":"crossref","DOI":"10.1016\/j.drugalcdep.2022.109294","article-title":"State-level regulations and opioid-related health outcomes","volume":"232","author":"Jackson","year":"2022","journal-title":"Drug and Alcohol Dependence"},{"key":"10.1016\/j.josat.2026.210060_bb0150","doi-asserted-by":"crossref","DOI":"10.1016\/j.jsat.2020.108008","article-title":"Characterizing variability in state-level regulations governing opioid treatment programs","volume":"115","author":"Jackson","year":"2020","journal-title":"Journal of Substance Abuse Treatment"},{"issue":"2","key":"10.1016\/j.josat.2026.210060_bb0155","doi-asserted-by":"crossref","first-page":"136","DOI":"10.1080\/10550887.2023.2165869","article-title":"Geographic variation in availability of opioid treatment programs across U.S. communities","volume":"42","author":"Jehan","year":"2024","journal-title":"Journal of Addictive Diseases"},{"issue":"12","key":"10.1016\/j.josat.2026.210060_bb0160","doi-asserted-by":"crossref","first-page":"2243","DOI":"10.1111\/add.15087","article-title":"Global opioid agonist treatment: A review of clinical practices by country","volume":"115","author":"Jin","year":"2020","journal-title":"Addiction"},{"issue":"5","key":"10.1016\/j.josat.2026.210060_bb0165","doi-asserted-by":"crossref","DOI":"10.1093\/haschl\/qxad061","article-title":"Methadone prescribing by addiction specialists likely to leave communities without available methadone treatment","volume":"1","author":"Joudrey","year":"2023","journal-title":"Health Affairs Scholar"},{"issue":"6","key":"10.1016\/j.josat.2026.210060_bb0170","doi-asserted-by":"crossref","DOI":"10.1093\/haschl\/qxae076","article-title":"Access to treatment before and after Medicare coverage of opioid treatment programs","volume":"2","author":"Liu","year":"2024","journal-title":"Health Affairs Scholar"},{"key":"10.1016\/j.josat.2026.210060_bb0175","article-title":"Integrating methadone services into primary care in Ukraine: Two-year outcomes from a randomized trial","author":"Machavariani","year":"2025","journal-title":"Annals of Internal Medicine"},{"issue":"9","key":"10.1016\/j.josat.2026.210060_bb0180","doi-asserted-by":"crossref","first-page":"1086","DOI":"10.1377\/hlthaff.2025.00207","article-title":"The quality of opioid use disorder treatment in Medicare is low and lags behind Medicaid","volume":"44","author":"Mark","year":"2025","journal-title":"Health Affairs"},{"key":"10.1016\/j.josat.2026.210060_bb0185","series-title":"The consistently low percentage of Medicare enrollees receiving medication to treat their opioid use disorder remains a concern (OEI-02-23-00250)","author":"Maxwell","year":"2023"},{"key":"10.1016\/j.josat.2026.210060_bb0190","series-title":"Medicare and Medicaid enrollees in many high-need areas may lack access to medications for opioid use disorder, OEI-BL-23-00160 (OEI-BL-23-00160)","author":"Maxwell","year":"2024"},{"issue":"9","key":"10.1016\/j.josat.2026.210060_bb0195","doi-asserted-by":"crossref","first-page":"804","DOI":"10.1176\/appi.ajp.2021.20101548","article-title":"Office-based methadone treatment for opioid use disorder and pharmacy dispensing: A scoping review","volume":"178","author":"McCarty","year":"2021","journal-title":"American Journal of Psychiatry"},{"key":"10.1016\/j.josat.2026.210060_bb0200","author":"National Rural Health Association"},{"key":"10.1016\/j.josat.2026.210060_bb0205","series-title":"Medicare fee-for-service beneficiaries with opioid use disorder in 2018: Disparities in prevalence by beneficiary characteristics (CMS OMH data highlight no. 21)","author":"Niles","year":"2020"},{"key":"10.1016\/j.josat.2026.210060_bb0210","series-title":"Key facts about medicare beneficiaries in rural areas","author":"Ochieng","year":"2025"},{"issue":"1","key":"10.1016\/j.josat.2026.210060_bb0215","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1186\/s13722-022-00316-3","article-title":"Cumulative barriers to retention in methadone treatment among adults from rural and small urban communities","volume":"17","author":"Pasman","year":"2022","journal-title":"Addiction Science & Clinical Practice"},{"issue":"4","key":"10.1016\/j.josat.2026.210060_bb0220","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0301863","article-title":"County-level factors associated with a mismatch between opioid overdose mortality and availability of opioid treatment facilities","volume":"19","author":"Rizk","year":"2024","journal-title":"PLoS One"},{"key":"10.1016\/j.josat.2026.210060_bb0225","doi-asserted-by":"crossref","DOI":"10.1016\/j.dadr.2026.100413","article-title":"Barriers and facilitators to methadone dispensing for opioid use disorder in community pharmacies: A scoping review","volume":"18","author":"Shubel","year":"2026","journal-title":"Drug and Alcohol Dependence Reports"},{"key":"10.1016\/j.josat.2026.210060_bb0230","article-title":"Mortality risk during and after opioid substitution treatment: Systematic review and meta-analysis of cohort studies","volume":"357","author":"Sordo","year":"2017","journal-title":"British Medical Journal (Clinical Research Edition)"},{"key":"10.1016\/j.josat.2026.210060_bb0235","series-title":"Federal guidelines for opioid treatment programs (HSS publication no. PEP24-02-011)","author":"Substance Abuse and Mental Health Services Administration","year":"2024"},{"key":"10.1016\/j.josat.2026.210060_bb0240","author":"Substance Abuse and Mental Health Services Administration"},{"key":"10.1016\/j.josat.2026.210060_bb0245","author":"Substance Abuse and Mental Health Services Administration"},{"key":"10.1016\/j.josat.2026.210060_bb0250","author":"Substance Abuse and Mental Health Services Administration"},{"key":"10.1016\/j.josat.2026.210060_bb0255","series-title":"Substance use and recovery services plan","author":"Substance Use and Recovery Services Advisory Committee","year":"2023"},{"key":"10.1016\/j.josat.2026.210060_bb0260","author":"Support for Patients and Communities Act of 2018"},{"issue":"7","key":"10.1016\/j.josat.2026.210060_bb0265","doi-asserted-by":"crossref","DOI":"10.1093\/haschl\/qxaf130","article-title":"Access to medication treatment for opioid use disorder in fee-for-service Medicare","volume":"3","author":"Taylor","year":"2025","journal-title":"Health Affairs Scholar"},{"key":"10.1016\/j.josat.2026.210060_bb0270","author":"U.S. Census Bureau"},{"key":"10.1016\/j.josat.2026.210060_bb0275","doi-asserted-by":"crossref","DOI":"10.1097\/ADM.0000000000000922","article-title":"Evidence of buprenorphine-precipitated withdrawal in persons who use fentanyl","author":"Varshneya","year":"2022","journal-title":"Journal of Addiction Medicine"}],"container-title":["Journal of Substance Use and Addiction Treatment"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2949875926001803?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2949875926001803?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,8,8]],"date-time":"2026-08-08T13:29:21Z","timestamp":1786195761000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2949875926001803"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,11]]},"references-count":55,"alternative-id":["S2949875926001803"],"URL":"https:\/\/doi.org\/10.1016\/j.josat.2026.210060","relation":{},"ISSN":["2949-8759"],"issn-type":[{"value":"2949-8759","type":"print"}],"subject":[],"published":{"date-parts":[[2026,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Methadone treatment in the rural and urban United States: Geographic barriers and regional variations in Medicare-enrolled opioid treatment program availability","name":"articletitle","label":"Article Title"},{"value":"Journal of Substance Use and Addiction Treatment","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.josat.2026.210060","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"210060"}}